Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

PET scans may improve bladder cancer staging

NCT ID NCT04053101

Knowledge-focused Sponsor: Institut Bergonié Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times

Summary

This study looked at whether FDG-PET CT scans can more accurately stage muscle invasive bladder cancer compared to standard CT scans. Researchers reviewed records of 130 patients who had PET CT scans at diagnosis. The goal was to see if PET CT better detects cancer spread to lymph nodes or other areas, which could guide treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FDG-PET CT scan
What this could lead to
If successful, this could show that PET CT scans are more accurate for staging bladder cancer, leading to better treatment decisions.
What could go wrong
This is a retrospective study, not a controlled trial, so results may not be definitive. The scans are for staging, not treatment, so direct patient benefit is limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

130 people

The number who actually took part.

Started

Apr 2017

Finished

Aug 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Every patient undergoing a PET CT at the time of diagnosis of muscle invasive bladder cancer from January 2005 to December 2017 in Bordeaux (Institut Bergonié and University Hospital).

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of Muscle Invasive Urothelial Carcinoma of the bladder (classified at least pT2 on TURB) * Diagnosis between January 2005 and December 2017 * PET CT done during initial assessment before surgery (at the time of diagnosis and/or after neoadjuvant chemotherapy) * Management of cancer at Institut Bergonié or at Bordeaux University Hospital * Previous treatment for Non Muscle Invasive Bladder Cancer allowed Exclusion Criteria: * Management of cancer outside of Institut Bergonié or Bordeaux University Hospital * No PET CT done during initial assessment (before surgery) * Rare pathological type of bladder cancer without urothelial carcinoma (epidermoid carcinoma, neuro-endocrine carcinoma, …) * Extra-vesical urothelial carcinoma

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Muscle invasive bladder cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Muscle invasive bladder cancer

Contacts and locations

Locations

  • Centre Hospitalier Universitaire de Bordeaux

    Bordeaux, 33076, France

  • Institut Bergonie

    Bordeaux, 33076, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.